Nedra Whitehead
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Nedra Whitehead has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
- Shiny Thomas
New York Department of Health, Albany, USA
4 shared publications Amir Shaygan
2 shared publications- Amy Moore
RTI International, Waltham, USA
2 shared publications - Barbara Do
RTI International, Research Triangle Park, USA
2 shared publications - Christine Hill
RTI International (Retired), Decatur, USA
2 shared publications Daniel C. Solis
2 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by Springer Nature in Journal of Clinical Sleep Medicine
- Vol. 22 (1) , 186
Correction: A systematic review of the frequency of sleep evaluations, sleep disorders, and treatments among individuals with muscular dystrophy
- 7 October 2026
- Published by Springer Nature in Journal of Clinical Sleep Medicine
- Vol. 22 (1) , 186
Open AccessCorrection: A systematic review of the frequency of sleep evaluations, sleep disorders, and treatments among individuals with muscular dystrophy
- 29 September 2026
- Published by Springer Nature in Journal of Clinical Sleep Medicine
- Vol. 22 (1) , 173
A systematic review of the frequency of sleep evaluations, sleep disorders, and treatments among individuals with muscular dystrophy
Purpose Review literature on the frequency of sleep disorders and receipt of sleep-related healthcare among individuals with muscular dystrophy. Methods Included: Population–Duchenne/Becker (DBMD), congenital (CMD), facioscapulohumeral (FSHD), limb-girdle (LGMD), or myotonic (DM) muscular dystrophy; Outcomes–frequency of sleep evaluations, disorders, or treatments; Language–English; Study type–original research, systematic review. Excluded: Sample Information sources: PubMed and EBSCO, last searched March 7, 2023. Risk of bias assessment : Recruitment source or study inclusion selected for or against sleep symptoms or disorders. Synthesis: Range and weighted average (low risk studies only) of outcome. Results We included 95 studies of sleep evaluations (7), disorders (94) or treatments (13) with a total of 7,964 participants. Studies reported on DM–61, DBMD–20, FSHD–9, CMD–1, LGMD–1, and multiple MD–3. One-half of people with DBMD (51%, 2 studies, 85 individuals) and over 60% of people with DM1 (65%, 2 studies, 327 individuals) had a sleep study. Measured by questionnaire, excessive daytime sleepiness frequency among adults with DM was 39% (DM2, 10, 284) to 65% (any DM, 6, 1195), 9% among controls (5, 199), and 6% to 13% among other MDs. Sleep apnea frequency was 11% (LGMD, 1, 18) to 65% (CMD, 1, 20). Assisted ventilation use was 5%–16% (DM). Conclusions Regular sleep evaluations may improve identification and treatment of sleep disorders and the physical and mental health of individuals with MD. Other Funding–US Centers for Disease Control and Prevention. Not registered.
- 29 September 2026
- Published by Springer Nature in Journal of Clinical Sleep Medicine
- Vol. 22 (1) , 173
A systematic review of the frequency of sleep evaluations, sleep disorders, and treatments among individuals with muscular dystrophy
Purpose Review literature on the frequency of sleep disorders and receipt of sleep-related healthcare among individuals with muscular dystrophy. Methods Included: Population–Duchenne/Becker (DBMD), congenital (CMD), facioscapulohumeral (FSHD), limb-girdle (LGMD), or myotonic (DM) muscular dystrophy; Outcomes–frequency of sleep evaluations, disorders, or treatments; Language–English; Study type–original research, systematic review. Excluded: Sample Information sources: PubMed and EBSCO, last searched March 7, 2023. Risk of bias assessment : Recruitment source or study inclusion selected for or against sleep symptoms or disorders. Synthesis: Range and weighted average (low risk studies only) of outcome. Results We included 95 studies of sleep evaluations (7), disorders (94) or treatments (13) with a total of 7,964 participants. Studies reported on DM–61, DBMD–20, FSHD–9, CMD–1, LGMD–1, and multiple MD–3. One-half of people with DBMD (51%, 2 studies, 85 individuals) and over 60% of people with DM1 (65%, 2 studies, 327 individuals) had a sleep study. Measured by questionnaire, excessive daytime sleepiness frequency among adults with DM was 39% (DM2, 10, 284) to 65% (any DM, 6, 1195), 9% among controls (5, 199), and 6% to 13% among other MDs. Sleep apnea frequency was 11% (LGMD, 1, 18) to 65% (CMD, 1, 20). Assisted ventilation use was 5%–16% (DM). Conclusions Regular sleep evaluations may improve identification and treatment of sleep disorders and the physical and mental health of individuals with MD. Other Funding–US Centers for Disease Control and Prevention. Not registered.
- Open Access
- 12 September 2025
- Published by Elsevier in AJPM Focus
- Vol. 5 (1) , 100443
Proximity to Healthcare Services Among Individuals With Duchenne Muscular Dystrophy
- 12 September 2025
- Published by Elsevier in AJPM Focus
- Vol. 5 (1) , 100443
Open AccessProximity to Healthcare Services Among Individuals With Duchenne Muscular Dystrophy
- Open Access
- 1 December 2023
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 9 (6) , e200113
Genetic Patterns of Selected Muscular Dystrophies in the Muscular Dystrophy Surveillance, Tracking, and Research Network
Background and Objectives To report the genetic etiologies of Emery-Dreifuss muscular dystrophy (EDMD), limb-girdle muscular dystrophy (LGMD), congenital muscular dystrophy (CMD), and distal muscular dystrophy (DD) in 6 geographically defined areas of the United States. Methods This was a cross-sectional, population-based study in which we studied the genes and variants associated with muscular dystrophy in individuals who were diagnosed with and received care for EDMD, LGMD, CMD, and DD from January 1, 2008, through December 31, 2016, in the 6 areas of the United States covered by the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). Variants of unknown significance (VUSs) from the original genetic test reports were reanalyzed for changes in interpretation. Results Among 243 individuals with definite or probable muscular dystrophy, LGMD was the most common diagnosis (138 cases), followed by CMD (62 cases), DD (22 cases), and EDMD (21 cases). There was a higher proportion of male individuals compared with female individuals, which persisted after excluding X-linked genes (EMD) and autosomal genes reported to have skewed gender ratios (ANO5, CAV3, and LMNA). The most common associated genes were FKRP, CAPN3, ANO5, and DYSF. Reanalysis yielded more definitive variant interpretations for 60 of 144 VUSs, with a mean interval between the original clinical genetic test of 8.11 years for all 144 VUSs and 8.62 years for the 60 reclassified variants. Ten individuals were found to have monoallelic pathogenic variants in genes known to be primarily recessive. Discussion This study is distinct for being an examination of 4 types of muscular dystrophies in selected geographic areas of the United States. The striking proportion of resolved VUSs demonstrates the value of periodic re-examinations of these variants. Such re-examinations will resolve some genetic diagnostic ambiguities before initiating repeat testing or more invasive diagnostic procedures such as muscle biopsy. The presence of monoallelic pathogenic variants in recessive genes in our cohort indicates that some individuals with muscular dystrophy continue to face incomplete genetic diagnoses; further refinements in genetic knowledge and diagnostic approaches will optimize diagnostic information for these individuals.
- 1 December 2023
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 9 (6) , e200113
Open AccessGenetic Patterns of Selected Muscular Dystrophies in the Muscular Dystrophy Surveillance, Tracking, and Research Network
Background and Objectives To report the genetic etiologies of Emery-Dreifuss muscular dystrophy (EDMD), limb-girdle muscular dystrophy (LGMD), congenital muscular dystrophy (CMD), and distal muscular dystrophy (DD) in 6 geographically defined areas of the United States. Methods This was a cross-sectional, population-based study in which we studied the genes and variants associated with muscular dystrophy in individuals who were diagnosed with and received care for EDMD, LGMD, CMD, and DD from January 1, 2008, through December 31, 2016, in the 6 areas of the United States covered by the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). Variants of unknown significance (VUSs) from the original genetic test reports were reanalyzed for changes in interpretation. Results Among 243 individuals with definite or probable muscular dystrophy, LGMD was the most common diagnosis (138 cases), followed by CMD (62 cases), DD (22 cases), and EDMD (21 cases). There was a higher proportion of male individuals compared with female individuals, which persisted after excluding X-linked genes (EMD) and autosomal genes reported to have skewed gender ratios (ANO5, CAV3, and LMNA). The most common associated genes were FKRP, CAPN3, ANO5, and DYSF. Reanalysis yielded more definitive variant interpretations for 60 of 144 VUSs, with a mean interval between the original clinical genetic test of 8.11 years for all 144 VUSs and 8.62 years for the 60 reclassified variants. Ten individuals were found to have monoallelic pathogenic variants in genes known to be primarily recessive. Discussion This study is distinct for being an examination of 4 types of muscular dystrophies in selected geographic areas of the United States. The striking proportion of resolved VUSs demonstrates the value of periodic re-examinations of these variants. Such re-examinations will resolve some genetic diagnostic ambiguities before initiating repeat testing or more invasive diagnostic procedures such as muscle biopsy. The presence of monoallelic pathogenic variants in recessive genes in our cohort indicates that some individuals with muscular dystrophy continue to face incomplete genetic diagnoses; further refinements in genetic knowledge and diagnostic approaches will optimize diagnostic information for these individuals.
- Open Access
- 22 March 2023
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 18 (1) , 1-10
Sources of variation in estimates of Duchenne and Becker muscular dystrophy prevalence in the United States
Background: Direct estimates of rare disease prevalence from public health surveillance may only be available in a few catchment areas. Understanding variation among observed prevalence can inform estimates of prevalence in other locations. The Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet) conducts population-based surveillance of major muscular dystrophies in selected areas of the United States. We identified sources of variation in prevalence estimates of Duchenne and Becker muscular dystrophy (DBMD) within MD STARnet from published literature and a survey of MD STARnet investigators, then developed a logic model of the relationships between the sources of variation and estimated prevalence. Results: The 17 identified sources of variability fell into four categories: (1) inherent in surveillance systems, (2) particular to rare diseases, (3) particular to medical-records-based surveillance, and (4) resulting from extrapolation. For the sources of uncertainty measured by MD STARnet, we estimated each source’s contribution to the total variance in DBMD prevalence. Based on the logic model we fit a multivariable Poisson regression model to 96 age–site–race/ethnicity strata. Age accounted for 74% of the variation between strata, surveillance site for 6%, race/ethnicity for 3%, and 17% remained unexplained. Conclusion: Variation in estimates derived from a non-random sample of states or counties may not be explained by demographic differences alone. Applying these estimates to other populations requires caution.
- 22 March 2023
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 18 (1) , 1-10
Open AccessSources of variation in estimates of Duchenne and Becker muscular dystrophy prevalence in the United States
Background: Direct estimates of rare disease prevalence from public health surveillance may only be available in a few catchment areas. Understanding variation among observed prevalence can inform estimates of prevalence in other locations. The Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet) conducts population-based surveillance of major muscular dystrophies in selected areas of the United States. We identified sources of variation in prevalence estimates of Duchenne and Becker muscular dystrophy (DBMD) within MD STARnet from published literature and a survey of MD STARnet investigators, then developed a logic model of the relationships between the sources of variation and estimated prevalence. Results: The 17 identified sources of variability fell into four categories: (1) inherent in surveillance systems, (2) particular to rare diseases, (3) particular to medical-records-based surveillance, and (4) resulting from extrapolation. For the sources of uncertainty measured by MD STARnet, we estimated each source’s contribution to the total variance in DBMD prevalence. Based on the logic model we fit a multivariable Poisson regression model to 96 age–site–race/ethnicity strata. Age accounted for 74% of the variation between strata, surveillance site for 6%, race/ethnicity for 3%, and 17% remained unexplained. Conclusion: Variation in estimates derived from a non-random sample of states or counties may not be explained by demographic differences alone. Applying these estimates to other populations requires caution.
- Open Access
- 1 June 2021
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 14, 679-680
From Clinical Phenotype to Genotypic Modelling: Incidence and Prevalence of Recessive Dystrophic Epidermolysis Bullosa (RDEB) [Corrigendum]
Corrigendum for the article From Clinical Phenotype to Genotypic Modelling: Incidence and Prevalence of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
- 1 June 2021
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 14, 679-680
Open AccessFrom Clinical Phenotype to Genotypic Modelling: Incidence and Prevalence of Recessive Dystrophic Epidermolysis Bullosa (RDEB) [Corrigendum]
Corrigendum for the article From Clinical Phenotype to Genotypic Modelling: Incidence and Prevalence of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
- 2 June 2020
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 18 (9) , 2274-2286
Recurrent thrombosis in patients with antiphospholipid antibodies and an initial venous or arterial thromboembolic event: A systematic review and meta‐analysis
- 2 June 2020
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 18 (9) , 2274-2286
Recurrent thrombosis in patients with antiphospholipid antibodies and an initial venous or arterial thromboembolic event: A systematic review and meta‐analysis
- Open Access
- 1 December 2019
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 12, 933-942
From Clinical Phenotype to Genotypic Modelling: Incidence and Prevalence of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Background: Recessive dystrophic epidermolysis bullosa (RDEB) is an inherited genetic disorder characterized by recurrent and chronic open wounds with significant morbidity, impaired quality of life, and early mortality. RDEB patients demonstrate reduction or structural alteration type VII collagen (C7) owing to mutations in the gene COL7A1, the main component of anchoring fibrils (AF) necessary to maintain epidermal-dermal cohesion. While over 700 alterations in COL7A1 have been reported to cause dystrophic epidermolysis bullosa (DEB), which may be inherited in an autosomal dominant (DDEB) or autosomal recessive pattern (RDEB), the incidence and prevalence of RDEB is not well defined. To date, the widely estimated incidence (0.2–6.65 per million births) and prevalence (3.5–20.4 per million people) of RDEB has been primarily characterized by limited analyses of clinical databases or registries. Methods: Using a genetic modelling approach, we use whole exome and genome sequencing data to estimate the allele frequency of pathogenic variants. Through the ClinVar and NCBI database of human genome variants and phenotypes, DEB Register, and analyzing premature COL7A1 termination variants we built a model to predict the pathogenicity of previously unclassified variants. We applied the model to publicly available sequences from the Exome Aggregation Consortium (ExAC) and Genome Aggregation Database (gnomAD) and identified variants which were classified as pathogenic for RDEB from which we estimate disease incidence and prevalence. Results: Genetic modelling applied to the whole exome and genome sequencing data resulted in the identification of predicted RDEB pathogenic alleles, from which our estimate of the incidence of RDEB is 95 per million live births, 30 times the 3.05 per million live birth incidence estimated by the National Epidermolysis Bullosa Registry (NEBR). Using a simulation approach, we estimate a mean of approximately 3,850 patients in the US who may benefit from COL7A1-mediated treatments in the US. Conclusion: We conclude that genetic allele frequency estimation may enhance the underdiagnosis of rare genetic diseases generally, and RDEB specifically, which may improve incidence and prevalence estimates of patients who may benefit from treatment.
- 1 December 2019
- Published by Taylor & Francis in Clinical, Cosmetic and Investigational Dermatology
- Vol. ume 12, 933-942
Open AccessFrom Clinical Phenotype to Genotypic Modelling: Incidence and Prevalence of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Background: Recessive dystrophic epidermolysis bullosa (RDEB) is an inherited genetic disorder characterized by recurrent and chronic open wounds with significant morbidity, impaired quality of life, and early mortality. RDEB patients demonstrate reduction or structural alteration type VII collagen (C7) owing to mutations in the gene COL7A1, the main component of anchoring fibrils (AF) necessary to maintain epidermal-dermal cohesion. While over 700 alterations in COL7A1 have been reported to cause dystrophic epidermolysis bullosa (DEB), which may be inherited in an autosomal dominant (DDEB) or autosomal recessive pattern (RDEB), the incidence and prevalence of RDEB is not well defined. To date, the widely estimated incidence (0.2–6.65 per million births) and prevalence (3.5–20.4 per million people) of RDEB has been primarily characterized by limited analyses of clinical databases or registries. Methods: Using a genetic modelling approach, we use whole exome and genome sequencing data to estimate the allele frequency of pathogenic variants. Through the ClinVar and NCBI database of human genome variants and phenotypes, DEB Register, and analyzing premature COL7A1 termination variants we built a model to predict the pathogenicity of previously unclassified variants. We applied the model to publicly available sequences from the Exome Aggregation Consortium (ExAC) and Genome Aggregation Database (gnomAD) and identified variants which were classified as pathogenic for RDEB from which we estimate disease incidence and prevalence. Results: Genetic modelling applied to the whole exome and genome sequencing data resulted in the identification of predicted RDEB pathogenic alleles, from which our estimate of the incidence of RDEB is 95 per million live births, 30 times the 3.05 per million live birth incidence estimated by the National Epidermolysis Bullosa Registry (NEBR). Using a simulation approach, we estimate a mean of approximately 3,850 patients in the US who may benefit from COL7A1-mediated treatments in the US. Conclusion: We conclude that genetic allele frequency estimation may enhance the underdiagnosis of rare genetic diseases generally, and RDEB specifically, which may improve incidence and prevalence estimates of patients who may benefit from treatment.
- Open Access
- 12 February 2018
- Published by RTI Press
Completeness of Prenatal Records in Community Hospital Charts
We describe the completeness of prenatal data in maternal delivery records and the prevalence of selected medical conditions and complications among patients delivering at community hospitals around Atlanta, Georgia. Medical charts for 199 maternal-infant dyads (99 infants in normal newborn nurseries and 104 infants in newborn intensive care nurseries) were identified by medical records staff at 9 hospitals and abstracted on site. Ninety-eight percent of hospital charts included prenatal records, but over 20 percent were missing results for common laboratory tests and prenatal procedures. Forty-nine percent of women had a pre-existing medical condition, 64 percent had a prenatal complication, and 63 percent had a labor or delivery complication. Missing prenatal information limits the usefulness of these records for research and may result in unnecessary tests or procedures or inappropriate medical care.
- 12 February 2018
- Published by RTI Press
Open AccessCompleteness of Prenatal Records in Community Hospital Charts
We describe the completeness of prenatal data in maternal delivery records and the prevalence of selected medical conditions and complications among patients delivering at community hospitals around Atlanta, Georgia. Medical charts for 199 maternal-infant dyads (99 infants in normal newborn nurseries and 104 infants in newborn intensive care nurseries) were identified by medical records staff at 9 hospitals and abstracted on site. Ninety-eight percent of hospital charts included prenatal records, but over 20 percent were missing results for common laboratory tests and prenatal procedures. Forty-nine percent of women had a pre-existing medical condition, 64 percent had a prenatal complication, and 63 percent had a labor or delivery complication. Missing prenatal information limits the usefulness of these records for research and may result in unnecessary tests or procedures or inappropriate medical care.
- Open Access
- 10 October 2013
- Published by RTI Press
PhenX: Establishing a consensus process to select common measures for collaborative research
The PhenX (consensus measures for Phenotypes and eXposures) Toolkit offers well-established, broadly validated measures of phenotypes and exposures relevant to investigators in human genomics, epidemiology, and biomedical research. This methods report describes the infrastructure and processes used to develop the content and features of the Toolkit. The PhenX consensus process is robust, yet flexible, as evidenced by its application to a range of research domains. During the initial phase of PhenX from March 2008 through April 2010, working groups of content experts addressed 21 research domains and selected 295 measures for the Toolkit. The PhenX Steering Committee prioritized and defined the scope of the domains and guided the consensus process with input from liaisons representing the National Institutes of Health. After the 21 domains were completed, another project to add breadth and depth to the Toolkit for substance abuse and addiction (SAA) research served to validate the consensus process. With the support of the SAA Scientific Panel to define the scope for one core and six specialty collections and SAA working groups to select measures, the PhenX project team added 44 measures to the Toolkit in 2012. The PhenX Toolkit, now being used by more than 1,000 researchers, offers a catalog of measures, supporting documentation, and tools for collaborative research. It used a consensus process that can serve as a template for investigators who are considering a similar approach.
- 10 October 2013
- Published by RTI Press
Open AccessPhenX: Establishing a consensus process to select common measures for collaborative research
The PhenX (consensus measures for Phenotypes and eXposures) Toolkit offers well-established, broadly validated measures of phenotypes and exposures relevant to investigators in human genomics, epidemiology, and biomedical research. This methods report describes the infrastructure and processes used to develop the content and features of the Toolkit. The PhenX consensus process is robust, yet flexible, as evidenced by its application to a range of research domains. During the initial phase of PhenX from March 2008 through April 2010, working groups of content experts addressed 21 research domains and selected 295 measures for the Toolkit. The PhenX Steering Committee prioritized and defined the scope of the domains and guided the consensus process with input from liaisons representing the National Institutes of Health. After the 21 domains were completed, another project to add breadth and depth to the Toolkit for substance abuse and addiction (SAA) research served to validate the consensus process. With the support of the SAA Scientific Panel to define the scope for one core and six specialty collections and SAA working groups to select measures, the PhenX project team added 44 measures to the Toolkit in 2012. The PhenX Toolkit, now being used by more than 1,000 researchers, offers a catalog of measures, supporting documentation, and tools for collaborative research. It used a consensus process that can serve as a template for investigators who are considering a similar approach.